VITVO

Catalog Number:
F000001
Supplier:
Rigenerand
Price:
$873
  • Size:
    6 pcs/package
    Quantity:
    Add to Cart:
      • Overview
        • A novel-generation 3D cell culture bioreactor for rapid cell colonization in a 3D manner enabling an in vitro real reconstruction of tissue complexity, in an in vivo-like microenvironment.
          VITVO it’s a ready to use, flat and handheld bioreactor, integrating scaffold for the establishment of in vitro 3D cell culture model that can be used for a large number of research applications and pre-clinical investigations. This in vitro 3D cell culture technology offers also a solution for precision medicine approaches.

          HOW TO WORK
          VITVO 3D Bioreactor’s matrix inner core is a fiber-based 3D scaffold optimized for cell retainment, engraftment, and colonization. Cells colonize within the 3D matrix by adhering to the fibers , or forming aggregates within 90% of its empty volume. Our cell culture bioreactor can host human and animal cells – making it a concrete solution for reducing and replacing small animal studies with both ethical and economic impacts in drug development.

          ADVANTAGES
          -Three dimensional (3D) platforms have potential to provide more physiologic environments for cell culture in drug discovery and toxicology than classical 2D culture systems.
          -3D culture allows a greater predictivity of efficacy and toxicity before putative drugs move into pre-clinical animal testing and towards clinics, lowering the attrition rate of drug development.
          -3D cultures retain the advantage to mimic an in vivo-like context enabling drug safety and efficacy testing in a human avatar environment.
          -3D culture leads to a different modulation of gene expression, ultimately influencing the antigenic profile of the cells and closely mimicking an in vivo environment.

          Please contact us at  for specific academic pricing.

      • Properties
        • Categories
          3D bioreactor
          Appearance
          Matrix volume: 4 cm2 (area) x 400 µm (thickness)
          Empty volume: 90% of matrix volume
          Other Properties
          Biological safety: Inert, biocompatible and xeno-free; DNAse/RNAse free
          Sterilization: Electron-beam processing
          Storage
          Two years shelf life

          * Research use only

      • Applications
        • Application Description
          • To address chemotherapy/TKI efficacy in 3D To minimize animal uses (3R)
          • To address cell therapies efficacy (possibility to load Targets and Effectors at variable ratios in a 3D relevant model CAR-T, MSC)
          • To address biologics efficacy in 3D (PD/PK), i.e tumor penetration of a monoclonal antibody
          • To address putative drug toxicity in 3D (hepatocytes)
          • To host tumor spheroids (Glioblastoma) also loaded in the two faces
          • Cancer metabolomics (i.e. tumor/stroma interaction)
          • Histology testing after cell loading (methacrylate embedding)
          • Histology testing after cytotoxicity (surrogate of minimal residual disease)
          • Migration assays in 3D

    Refernce

    Corallo Diana, Frabetti Stella, Candini Olivia, Gregianin Elisa, Dominici Massimo, Fischer Horst, Aveic Sanja. Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments. Frontiers in Immunology, 26 November 2020
    Golinelli G, Mastrolia I, Aramini B, Masciale V, Pinelli M, Pacchioni L, Casari G, Dall’Ora M, Soares MBP, Damasceno PKF, Silva DN, Dominici M and Grisendi G. Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come? Front. Pharmacol., 29 September 2020.
    Candini O, Grisendi G, Foppiani EM, Brogli M, Aramini B, Masciale V, Spano C, Petrachi T, Veronesi E, Conte P, Mari G, Dominici M. A Novel 3D In Vitro platform for pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology. Scientific Reports 9:7154 (2019).
    Rossignoli F, Spano C, Grisendi G, Foppiani EM, Golinelli G, Mastrolia I, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Veronesi E, Medici G, Petocchi B, Pinelli M, Horwitz EM, Conte P, Dominici M. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics 2019; 9(2):436-448.
    Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep. 2019 Feb 11;9(1):1788.
    Golinelli G, Grisendi G, Prapa M, Bestagno M, Spano C, Rossignoli F, Bambi F, Sardi I, Cellini M, Horwitz EM, Feletti A, Pavesi G, Dominici M. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 2018 Nov 22.
    Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti G, Orsi G, Veronesi E, Horwitz EM, Dominici M. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Ther. 2019 Feb;26(1-2):11-16.
    Relation T, Dominici M, Horwitz EM. Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells. Stem Cells. 2017 May;35(5):1123-1130.
    Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M, Redini F. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Int J Cancer. 2016 Dec 15;139(12):2802-2811.
    Grisendi G, Spano C, Rossignoli F, D Souza N, Golinelli G, Fiori A, Horwitz EM, Guarneri V, Piacentini F, Paolucci P, Dominici M. Tumor Stroma Manipulation By MSC. Curr Drug Targets. 2016;17(10):1111-26.
    Veronesi E, Burns JS, Murgia A, Candini O, Rasini V, Mastrolia I, Catani F, Paolucci P, Dominici M. cGMP-compliant transportation conditions for a prompt therapeutic use of marrow mesenchymal stromal/stem cells. Methods Mol Biol. 2015;1283:109-22.
    D’souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, Osturu S, Catani F, Paolucci P, Horwitz EM, Dominici M. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015 Aug 12;13:186.
    Grisendi G, Spano C, D’souza N, Rasini V, Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns JS, Fiorcari S, Granchi D, Baldini N, Horwitz EM, Guarneri V, Conte P, Paolucci P, Dominici M. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas. Stem Cells. 2015 Mar;33(3):859-69.
    Golinelli G, Grisendi G, Spano C, Dominici M. Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal/stem cells. Hum Gene Ther. 2014 May;25(5):406-7.
    D’souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M. MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Adv Biochem Eng Biotechnol. 2013;130:209-66.
    Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P, Paolucci P, Horwiz EM, Dominici M. Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. Biomed Res Int. 2013;2013:901821.
    Piccinno MS, Veronesi E, Loschi P, Pignatti M, Murgia A, Grisendi G, Castelli I, Bernabei D, Candini O, Conte P, Paolucci P, Horwitz EM, De Santis G, Iughetti L, Dominici M. Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. Apoptosis. 2013 Oct;18(10):1274-89.
    Copyright © Amerigo Scientific. All rights reserved.